On Tuesday, Elevation Oncology Inc (NASDAQ: ELEV) opened higher 11.71% from the last session, before settling in for the closing price of $0.59. Price fluctuations for ELEV have ranged from $0.36 to $5.83 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 41.26% at the time writing. With a float of $49.99 million, this company’s outstanding shares have now reached $59.11 million.
The extent of productivity of a business whose workforce counts for 29 workers is very important to gauge. In terms of profitability, gross margin is 43.1%, operating margin of -68444.83%, and the pretax margin is -68381.03%.
Elevation Oncology Inc (ELEV) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Elevation Oncology Inc is 15.43%, while institutional ownership is 84.44%.
Elevation Oncology Inc (ELEV) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.25 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.32) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 41.26% per share during the next fiscal year.
Elevation Oncology Inc (NASDAQ: ELEV) Trading Performance Indicators
Check out the current performance indicators for Elevation Oncology Inc (ELEV). In the past quarter, the stock posted a quick ratio of 41.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.84, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.83 in one year’s time.
Technical Analysis of Elevation Oncology Inc (ELEV)
The latest stats from [Elevation Oncology Inc, ELEV] show that its last 5-days average volume of 0.9 million was inferior to 1.62 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 79.99%. Additionally, its Average True Range was 0.05.
During the past 100 days, Elevation Oncology Inc’s (ELEV) raw stochastic average was set at 4.01%, which indicates a significant decrease from 85.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.62% in the past 14 days, which was lower than the 171.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6345, while its 200-day Moving Average is $2.6788. Now, the first resistance to watch is $0.6924. This is followed by the second major resistance level at $0.7311. The third major resistance level sits at $0.7823. If the price goes on to break the first support level at $0.6025, it is likely to go to the next support level at $0.5513. Assuming the price breaks the second support level, the third support level stands at $0.5126.
Elevation Oncology Inc (NASDAQ: ELEV) Key Stats
There are currently 54,638K shares outstanding in the company with a market cap of 38.64 million. Presently, the company’s annual sales total 0 K according to its annual income of -45,700 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -10,460 K.
